Moderna Surges 177% as Intismeran Clears Phase 3 Melanoma Trial

Moderna (MRNA) closed at $174.38 on August 19, up 177% from $62.96 the prior session. The trigger: the first Phase 3 win for the company’s personalized mRNA cancer vaccine, intismeran autogene (also known as V940 or mRNA-4157), developed in partnership with Merck (MRK). Merck shares rose about 12% the same day, reflecting the gap between a $25 billion company and a $333 billion one.

The Phase 3 INTerpath-001 trial enrolled 1,137 patients with completely resected stage IIB-IV melanoma. Two-thirds were randomized to receive intismeran plus Keytruda (pembrolizumab); the remaining third received Keytruda alone. At a pre-planned interim analysis, independent data monitors found the combination met its primary endpoint of recurrence-free survival (RFS) with a statistically significant and clinically meaningful improvement over Keytruda alone. The combination also met the key secondary endpoint of distant metastasis-free survival (DMFS).

The companies did not release the hazard ratio. Detailed data will be presented at an upcoming medical meeting. Until then, investors are pricing in a result that one analyst, TD Cowen’s Tyler Van Buren, called a “landmark moment.”

Why This Matters for Moderna

Moderna entered August 19 with a market cap near $25 billion, down from a COVID-era peak above $150 billion. The company’s post-pandemic thesis rested on two pillars: its respiratory vaccine franchise (flu, RSV, COVID boosters) and its oncology pipeline. The respiratory franchise has been rocky, as covered in our analysis of Moderna’s mFLUSIVA launch and the norovirus program stalling. The cancer vaccine program was the binary catalyst that would either justify the valuation or collapse it.

The Phase 3 hit. Moderna’s market cap jumped to roughly $69 billion on the close, adding $44 billion in market value in a single session. That is not irrational exuberance. Jefferies analyst Andrew Tsai projected billions in sales from the melanoma indication alone, and the platform is being tested in lung, kidney, and bladder cancer trials that could expand the addressable market by 3x to 5x.

The Phase 2 Benchmark

The Phase 2 data from 157 patients showed the intismeran-Keytruda combination reduced the relative risk of death or recurrence by 44% compared to Keytruda alone. Keytruda itself reduces recurrence risk by 43% versus placebo based on the KEYNOTE-054 trial. The Phase 3 was designed to confirm whether the 44% incremental benefit holds in a larger, more diverse population.

Analysts set their own benchmarks. Evercore ISI’s Cory Kasimov wrote that anything below 25% relative risk reduction would be “underwhelming,” while 35% to 40% would be “clearly differentiated.” The fact that independent monitors called the result “clinically meaningful” at the interim check suggests the effect size cleared the bar analysts set. But the exact number matters, and the market will not have it until the medical meeting presentation.

The Commercial Setup

Melanoma accounts for only about 1% of skin cancers but causes the large majority of skin cancer deaths. In the adjuvant setting (after surgical removal), the standard of care is Keytruda. The pitch is simple: add a personalized vaccine on top of the standard of care and keep more patients disease-free.

The “personalized” part is the manufacturing story. Every tumor has a unique set of mutations. Intismeran targets up to 34 neoantigens identified through sequencing of each patient’s tumor, then encodes them into an mRNA vaccine that trains the immune system to recognize and attack those specific cancer markers. This is not a one-size-fits-all drug. It is a manufacturing process that produces a custom therapy per patient.

That manufacturing complexity is both the bull case (proprietary, difficult to replicate) and the bear case (expensive, slow, hard to scale). The price has not been set. Keytruda costs roughly $150,000 per year in the adjuvant melanoma setting. Adding a personalized mRNA vaccine on top will not be cheap.

What Happens Next

The trial continues. The companies will present detailed RFS and DMFS data at an upcoming medical meeting. Dr. Dean Li, president of Merck Research Laboratories, told CNBC that the drugmakers plan to start talking to regulatory agencies about the treatment “in the next few months.”

Two catalysts to watch:

1. The detailed data presentation. The hazard ratio for RFS will determine whether analysts model $2 billion or $5 billion in peak sales. A 44% relative risk reduction (matching Phase 2) supports the higher end. A 25% to 30% reduction supports the lower end.

2. The INTerpath-002 readout in kidney cancer. Expected late 2026 or early 2027. Kidney cancer is a “hot” tumor with better immune infiltration, meaning the neoantigen vaccine approach may work even better. A win in kidney cancer doubles the addressable market.

3. Regulatory filing. If the FDA accepts a Biologics License Application (BLA) based on the interim data, approval could come in 2027. The accelerated approval pathway is available for therapies showing a meaningful improvement in an unmet need setting, as detailed in our guide to accelerated approval.

The Stock Reaction: Asymmetric

Moderna’s 177% single-day move reflects the binary nature of the catalyst. Before the announcement, the stock was pricing in failure. Leerink Partners analyst Mani Foroohar had called the Phase 3 a “make-or-break event” in a June note. The market was short the stock into the readout.

The day after, August 20, Moderna fell about 20% in early trading as the initial spike faded. This is the pattern we described in our guide to after-hours trading around FDA decisions: the initial spike partially reverses as institutional traders model the label and the timeline.

For investors who were already holding, the question is whether to sell into the fade or hold for the detailed data presentation. The answer depends on position size. A 177% gain on a 2% portfolio position is a 3.5% portfolio contribution. Selling half locks in the gain while maintaining exposure to the kidney cancer readout.

For investors who missed the move, the 20% pullback is the first entry point. The next catalyst (detailed data) is weeks to months away. The risk is that the hazard ratio disappoints, in which case the stock gives back 30% to 40% of the move. The upside is that the hazard ratio beats Phase 2, in which case the stock makes new highs.

The Platform Thesis

The melanoma win validates the mRNA cancer vaccine platform. Moderna is not a one-trick pony anymore. The same mRNA technology that delivered a COVID vaccine in 11 months is now delivering a cancer vaccine that clears Phase 3. The platform thesis is simple: if intismeran works in melanoma, it can work in any tumor type where neoantigens can be identified and the immune system can be activated.

That is a big “if.” But the Phase 2 data showed a 44% relative risk reduction, and the Phase 3 confirmed it. The next tests are kidney, bladder, and non-small cell lung cancer. Each one that hits expands the addressable market by $1 billion to $3 billion in peak sales.

For our earlier analysis of the cancer vaccine competitive field across three platforms, see cancer vaccines: three platforms, one winner. For Moderna’s broader platform thesis and how it compares to BioNTech, see our Moderna and BioNTech platform analysis.

Moderna at $69 billion market cap is pricing in melanoma success plus optionality in kidney, bladder, and lung. The downside if the detailed data disappoints is 30% to 40%. The upside if the kidney cancer readout hits is 50% to 100%. This is not a coin flip. It is a bet on a platform that just cleared its first real test.